aTyr Pharma
ATYR
33 hedge funds and large institutions have $57.2M invested in aTyr Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 5 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
8% more capital invested
Capital invested by funds: $53.1M → $57.2M (+$4.07M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.31% less ownership
Funds ownership: 66.89% → 66.57% (-0.31%)
8% less funds holding
Funds holding: 36 → 33 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
82% less call options, than puts
Call options by funds: $72K | Put options by funds: $403K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$1.36M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$357K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$286K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$161K |
| 5 |
TI
Telemetry Investments
New York
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$823K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$580K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$57K |
| 4 |
VF
Virtu Financial
New York
|
-$36K |
| 5 |
Jane Street
New York
|
-$29K |
ATYR Hedge Fund Activity: Q3 2022 in Review
33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2022, worth a combined $57.2M — up 7.7% from $53.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ATYR and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 14 added.
The largest buyer was Walleye Capital, opening a new position worth an estimated $1.36M. The largest seller was Deep Track Capital, exiting entirely with an estimated $823K sold.
- 33 institutional investors held aTyr Pharma (ATYR) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $57.2M of aTyr Pharma stock for Q3 2022, up 7.7% quarter-over-quarter.
- 2 funds opened new aTyr Pharma positions in Q3 2022 and 5 closed out, a net change of -3 holders.
- The largest aTyr Pharma buyer in Q3 2022 was Walleye Capital, an estimated $1.36M added.
- The largest aTyr Pharma seller in Q3 2022 was Deep Track Capital, an estimated $823K sold.
Based on aggregated 13F filings for Q3 2022.